Imneskibart enters the ASCO spotlight as Aulos Bioscience tests a smarter IL-2 strategy in melanoma

Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.

Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.